Stream 3: Original Research
Assessing key model parameters for economic evaluation of pandemic influenza interventions: the data source matters
Version of Record online: 27 AUG 2013
© 2013 Blackwell Publishing Ltd
Influenza and Other Respiratory Viruses
Special Issue: Proceedings from the WHO Meeting on Global Research for Influenza. Guest Editor: Nahoko Shindo. Publication of this supplement was supported by the Government of Japan
Volume 7, Issue Supplement s2, pages 59–63, September 2013
How to Cite
2013) Assessing key model parameters for economic evaluation of pandemic influenza interventions: the data source matters. Influenza and Other Respiratory Viruses 7(Suppl. 2), 59–63.et al. (
- Issue online: 27 AUG 2013
- Version of Record online: 27 AUG 2013
- Thailand Research Fund. Grant Number: RTA5580010
- Thai Health Promotion Foundation
- Health System Research Institute
- Bureau of Health Policy and Strategy
- Ministry of Public Health
- costs and cost analysis;
- disease outbreaks;
- economic evaluation models;
- human influenza;
- model parameters;
In our previous systematic review of economic evaluations of pandemic influenza interventions, five model parameters, namely probability of pandemic, duration of pandemic, severity, attack rate, and intervention efficacy, were not only consistently used in all studies but also considered important by authors.
Because these parameters originated from sources of varying quality ranging from experimental studies to expert opinion, this study aims to analyze the variation in values used according to sources of information across studies.
An analysis of estimated values of key parameters for economic modeling was performed against their different data sources, following the standard hierarchy of evidence.
A lack of good-quality evidence to estimate pandemic duration, pandemic probability, and mortality reduction from antiviral treatment results in a large variation of values used in economic evaluations. Although there are variations in quality of evidence used for attack rate, basic reproduction number, and reduction in hospitalizations from antiviral treatment, the estimated values do not vary significantly. The use of higher-quality evidence results in better precision of estimated values compared to lower-quality sources.
Hierarchies of evidence are a necessary tool to identify appropriate model parameters to populate economic evaluations and should be included in methodological guidelines. Knowledge gaps in some key parameters should be addressed, because if good-quality evidence is available, future economic evaluations will be more reliable. Some gaps may not be fulfilled by research but consensus among experts to ensure consistency in the use of these assumptions.